期刊文献+

核黄素磷酸钠粉针处方及制备工艺研究 被引量:4

A Study on the Formulation and Preparation Technology of Riboflavin Sodium Phosphate Injectable Powder
下载PDF
导出
摘要 目的通过试验确定核黄素磷酸钠粉针剂的处方和制备工艺。方法通过对冻干品的外观、含量、含水量、复溶性和溶解后澄明度等指标的考察确定最佳的支撑剂种类和用量、药液处理方法和冻干工艺参数。结果冻干前处方组成为核黄素磷酸钠13.69 g、焦亚硫酸钠2.0 g、EDTA-2Na 1.0 g、溶解于2000 ml蒸馏水中,室温下加0.10%(W/V)针用活性炭搅拌30 min除热原,0.22μm微孔滤膜滤过除菌,分装1000瓶,然后经-70℃预冻5 h,冻干机隔板-35℃预冻3 h,-15℃真空干燥12 h,15℃再干燥4 h即得。结论核黄素磷酸钠粉针处方合理,制备工艺可行。 Objective To determine the formulation and preparation technology of Riboflavin Sodium Phosphate injectable powder by experiments.Methods The appearance,drug content,water content,solubility and clarity of the freeze-died substace after dissolution were investigated to determine the kind and amount of support agents used,pre-processing methods of drug solution before freezing and the parameters of the freeze-drying process.Results The pre-freezing formulation consisted of riboflavin sodium phosphate 13.69 g,sodium pyrosulfite 2.0 g,EDTA-2Na 1.0 g,all of which were dissolved with 2000 ml of distilled water.0.10%(W/V)absorbite(injection grade)was added into the solution and agitated for 30 min at room temperature to remove the pyrogen.The solution was filtered with the 0.22 μm micropore film to remove the bacteria,subpackaged to 1000 bottles,and left frozen at-70℃ for 5h in a refrigerator,frozen at-35℃ for 3h in a freeze dryer,vacuum drying at-15℃ for 12h and drying again at 15℃ for 4h,before the freeze drying powder was finally obtained.Conclusion The formulation of Riboflavin Sodium Phosphate injectable powder we got seems acceptable and the preparation technology is feasible.
出处 《解放军药学学报》 CAS 2011年第4期314-317,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 核黄素磷酸钠 粉针 处方 制备工艺 riboflavin saodium phosphate injectable powder formulation preparation technology
  • 相关文献

参考文献5

二级参考文献24

  • 1曹履先,陈虎,江岷,胡亮钉,曾堂清,刘惠兰.同种异基因骨髓移植治疗白血病的临床研究[J].山西白血病,1992,1(4):208-213. 被引量:2
  • 2荣新洲,肖光,夏黎鳌,张雅萍,唐成功.核黄素对烧伤后早期损害的防治作用[J].第三军医大学学报,1996,18(5):387-389. 被引量:5
  • 3Mulherin DM, Thumham DI, Situnayake-RD, et al. Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis. [J]. Ann Rheum Dis, 1996,55( 11 ) :837 - 840.
  • 4Shoffner JM, Wallace DC. Oxidative phosphorylation diseases and mitochondrial DNA mutatiocs: diagnosis and treatment[J]. Annu Rev Nutr, 1994,14: 535 - 568.
  • 5Kerr DS. Protean manifestations of mitochondrial diseases: a minireview[J] .J Pediatr Hematol Oncol, 1997,19(4) :279- 286.
  • 6Ave'yanov AA, Lapikova VP, Nikolaev ON, et al. Active oxygenassociated control of rice blast disease by ~riboflavin and roseoflavin[J]. Biochemistry (Mosc), 2000,65(11):1292- 1298.
  • 7Helveston W,Cibula JE,Hurd R, et al. Abnormalities of antioxidant metabolism in a case of Friedrelch's disease[J]. Clin Neuropharmacol, 1996, 19(3) :271 - 275.
  • 8Morris AA, Leonard JV. The treatment of congenital lactic acidoses[J]. J Inherit Metab Dis, 1996,19(4): 573-580.
  • 9Kodentsova VM, Vrzhesinskaia OA, Trofimenko-EV, et al. Metabolism of some vitamins in children with insulin-dependent diabetes mellitus: importance of the disease duration, severity and metabolism impairment[J] . Vopr Med Khim, 1994,40(4):33-38.
  • 10Novikov DA, Provotorov VIa, Khabarov AA, et al. The demonstration of a hepatitis syndrome by an index of vitamin B2 excretion.[J].Voen Med Zh, 2000,321(6):65-67.

共引文献32

同被引文献46

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部